Novel pharmacological targets for the rhythm control management of atrial fibrillation

Pharmacology and Therapeutics

Volumn 132, Issue 3, 2011, Pages 300-313

  Burashnikov, Alexander ^a   Antzelevitch, Charles ^a  

^a MASONIC MEDICAL RESEARCH LABORATORY   (United States)

Author keywords

Antiarrhythmic therapy; Atrial fibrillation; Cardiac arrhythmias; Pharmacological treatment

Indexed keywords

2' (4 METHOXYPHENYLACETAMIDOMETHYL) N [2 (3 PYRIDYL)ETHYL] 2 BIPHENYLCARBOXAMIDE; ALDOSTERONE ANTAGONIST; AMIODARONE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; AZD 1305; DANEGAPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; DOFETILIDE; DRONEDARONE; FLECAINIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INAKALANT; ION CHANNEL; LIDOCAINE; OMEGA 3 FATTY ACID; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL KV1.5; PROCAINAMIDE; PROPAFENONE; QUINIDINE; RANOLAZINE; ROTIGAPTIDE; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT; SOTALOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERNAKALANT;

ACUTE CORONARY SYNDROME; ANTIARRHYTHMIC ACTIVITY; ARTICLE; BINDING AFFINITY; CALCIUM TRANSPORT; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; FOLLOW UP; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART INFARCTION; HEART MUSCLE POTENTIAL; HEART RATE; HEART RHYTHM; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HUMAN; HYPERTENSION; IC 50; ISCHEMIC HEART DISEASE; MITRAL VALVE REGURGITATION; NONHUMAN; PATIENT SAFETY; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; QT PROLONGATION; QUALITY OF LIFE; SINUS RHYTHM; TORSADE DES POINTES; TREATMENT OUTCOME; TREATMENT RESPONSE; VALVULAR HEART DISEASE;

EID: 80054998466     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2011.08.002     Document Type: Review

References (211)

1. O. Adam, G. Frost, F. Custodis, M.A. Sussman, H.J. Schafers, and M. Bohm Role of Rac1 GTPase activation in atrial fibrillation J Am Coll Cardiol 50 2007 359 367 (Pubitemid 47064499)
2. P. Alboni, G.L. Botto, N. Baldi, M. Luzi, V. Russo, and L. Gianfranchi Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach N Engl J Med 351 2004 2384 2391 (Pubitemid 40485990)
3. E. Aliot, A. Capucci, H.J. Crijns, A. Goette, and J. Tamargo Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation Europace 13 2011 161 173
4. H. Almroth, N. Hoglund, K. Boman, A. Englund, S. Jensen, and B. Kjellman Atorvastatin and persistent atrial fibrillation following cardioversion: a randomized placebo-controlled multicentre study Eur Heart J 30 2009 827 833
5. G.J. Amos, E. Wettwer, F. Metzger, Q. Li, H.M. Himmel, and U. Ravens Differences between outward currents of human atrial and subepicardial ventricular myocytes J Physiol 491 Pt. 1 1996 31 50 (Pubitemid 26059547)
6. S.S. Andersen, M.L. Hansen, G.H. Gislason, T.K. Schramm, F. Folke, and E. Fosbol Antiarrhythmic therapy and risk of death in patients with atrial fibrillation: a nationwide study Europace 11 2009 886 891
7. E. Anter, and D.J. Callans Pharmacological and electrical conversion of atrial fibrillation to sinus rhythm is worth the effort Circulation 120 2009 1436 1443
8. C. Antzelevitch Ranolazine: a new antiarrhythmic agent for patients with non-ST-segment elevation acute coronary syndromes? Nat Clin Pract Cardiovasc Med 5 2008 248 249 (Pubitemid 351605834)
9. C. Antzelevitch, L. Belardinelli, L. Wu, H. Fraser, A.C. Zygmunt, and A. Burashnikov Electrophysiologic properties and antiarrhythmic actions of a novel anti-anginal agent J Cardiovasc Pharmacol Ther 9 Suppl. 1 2004 S65 S83
10. C. Antzelevitch, and A. Burashnikov Atrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation J Electrocardiol 42 2009 543 548
11. C. Antzelevitch, A. Burashnikov, S. Sicouri, and L. Belardinelli Electrophysiological basis for the antiarrhythmic actions of ranolazine Heart Rhythm 8 2011 1281 1290
12. C. Antzelevitch, W. Shimizu, G.X. Yan, S. Sicouri, J. Weissenburger, and V.V. Nesterenko The M cell: Its contribution to the ECG and to normal and abnormal electrical function of the heart J Cardiovasc Electrophysiol 10 1999 1124 1152 (Pubitemid 29383677)
13. M.F. Arnsdorf, E. Schreiner, M. Gambetta, I. Friedlander, and R.W. Childers Electrophysiological changes in the canine atrium and ventricle during progressive hyperkalaemia: electrocardiographical correlates and the in vivo validation of in vitro predictions Cardiovasc Res 11 1977 409 418 (Pubitemid 8198636)
14. K. Ashikaga, T. Kobayashi, M. Kimura, S. Owada, S. Sasaki, and A. Iwasa Effects of amiodarone on electrical and structural remodeling induced in a canine rapid pacing-induced persistent atrial fibrillation model Eur J Pharmacol 536 2006 148 153
15. J.E. Banchs, D.L. Wolbrette, S.M. Samii, E.D. Penny-Peterson, P.P. Patel, and S.K. Young Efficacy and safety of dofetilide in patients with atrial fibrillation and atrial flutter J Interv Card Electrophysiol 23 2008 111 116
16. G.H. Bardy, K.L. Lee, D.B. Mark, J.E. Poole, D.L. Packer, and R. Boineau Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure N Engl J Med 352 2005 225 237 (Pubitemid 40110811)
17. S.S. Barold, M.D. Falkoff, L.S. Ong, and R.A. Heinle Hyperkalemia-induced failure of atrial capture during dual-chamber cardiac pacing J Am Coll Cardiol 10 1987 467 469 (Pubitemid 17127442)
18. E.P. Baskin, and J.J. Lynch Jr. Differential atrial versus ventricular activities of class III potassium channel blockers J Pharmacol Exp Ther 285 1998 135 142 (Pubitemid 28207578)
19. J. Bechard, J.K. Gibson, C.R. Killingsworth, J.J. Wheeler, M.J. Schneidkraut, and J. Huang Vernakalant selectively prolongs atrial refractoriness with no effect on ventricular refractoriness or defibrillation threshold in pigs J Cardiovasc Pharmacol 57 2011 302 307
20. J. Bechard, and M. Pourrier Atrial selective effects of intravenously administrated vernakalant in conscious beagle dog J Cardiovasc Pharmacol 58 2011 49 55
21. M. Bettoni, and M. Zimmermann Autonomic tone variations before the onset of paroxysmal atrial fibrillation Circulation 105 2002 2753 2759 (Pubitemid 34615147)
22. L. Bianconi, L. Calo, M. Mennuni, L. Santini, P. Morosetti, and P. Azzolini n-3 polyunsaturated fatty acids for the prevention of arrhythmia recurrence after electrical cardioversion of chronic persistent atrial fibrillation: a randomized, double-blind, multicentre study Europace 13 2011 174 181
23. G.E. Billman, and M. Kukielka Novel transient outward and ultra-rapid delayed rectifier current antagonist, AVE0118, protects against ventricular fibrillation induced by myocardial ischemia J Cardiovasc Pharmacol 51 2008 352 358 (Pubitemid 351572233)
24. Y. Blaauw, H. Gogelein, R.G. Tieleman, H.A. van, U. Schotten, and M.A. Allessie "Early" class III drugs for the treatment of atrial fibrillation: efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat Circulation 110 2004 1717 1724 (Pubitemid 39299211)
25. Y. Blaauw, U. Schotten, H.A. van, H.R. Neuberger, and M.A. Allessie Cardioversion of persistent atrial fibrillation by a combination of atrial specific and non-specific class III drugs in the goat Cardiovasc Res 75 2007 89 98 (Pubitemid 46873519)
26. R. Bogdan, H. Goegelein, and H. Ruetten Effect of dronedarone on Na(+), Ca (2+) and HCN channels Naunyn Schmiedebergs Arch Pharmacol 383 2011 347 356
27. L.V. Buchanan, R.J. LeMay, R.R. Walters, C.Y. Hsu, M.N. Brunden, and J.K. Gibson Antiarrhythmic and electrophysiologic effects of intravenous ibutilide and sotalol in the canine sterile pericarditis model J Cardiovasc Electrophysiol 7 1996 113 119 (Pubitemid 26056065)
28. A. Burashnikov Are there atrial selective/predominant targets for "upstream" atrial fibrillation therapy? Heart Rhythm 5 2008 1294 1295
29. A. Burashnikov, and C. Antzelevitch Acceleration-induced action potential prolongation and early afterdepolarizations J Cardiovasc Electrophysiol 9 1998 934 948 (Pubitemid 28455963)
30. A. Burashnikov, and C. Antzelevitch Prominent IKs in epicardium and endocardium contributes to development of transmural dispersion of repolarization but protects against development of early afterdepolarizations J Cardiovasc Electrophysiol 13 2002 172 177 (Pubitemid 34211922)
31. A. Burashnikov, and C. Antzelevitch Reinduction of atrial fibrillation immediately after termination of the arrhythmia is mediated by late phase 3 early afterdepolarization-induced triggered activity Circulation 107 2003 2355 2360 (Pubitemid 36578508)
32. A. Burashnikov, and C. Antzelevitch Late-phase 3 EAD. A unique mechanism contributing to initiation of atrial fibrillation PACE 29 2006 290 295 (Pubitemid 43881405)
33. A. Burashnikov, and C. Antzelevitch Atrial-selective sodium channel blockers: do they exist? J Cardiovasc Pharmacol 52 2008 121 128
34. Kur promote atrial fibrillation? Heart Rhythm 5 2008 1304 1309
35. A. Burashnikov, and C. Antzelevitch How do atrial-selective drugs differ from antiarrhythmic drugs currently used in the treatment of atrial fibrillation? J Atrial Fibrillation 1 2008 98 107
36. A. Burashnikov, and C. Antzelevitch Atrial-selective sodium channel block for the treatment of atrial fibrillation Expert Opin Emerg Drugs 14 2009 233 249
37. A. Burashnikov, and C. Antzelevitch New development in atrial antiarrhythmic drug therapy Nat Rev Cardiol 7 2010 139 148
38. A. Burashnikov, and C. Antzelevitch Absence of early afterdepolarizations in canine atria under long QT syndrome Heart Rhythm 8 5S 2011 S328 [Ref Type: Abstract]
39. A. Burashnikov, and C. Antzelevitch Activation of IK-ATP with low therapeutic concetrations of pinacidil leads to preferential abbreviation of repolarization in atria and inducible arrhythmias in atria but not ventricles Heart Rhythm 8 5S 2011 S466 [Ref Type: Abstract]
40. A. Burashnikov, H. Barajas-Martinez, D. Hu, E. Nof, J. Blazek, and C. Antzelevitch The atrial-selective potassium channel blocker AVE0118 prolongs effective refractory period in canine atria by inhibiting sodium channels Heart Rhythm 6 2009 S98 [Abstract]
41. A. Burashnikov, J.M. Di Diego, S. Sicouri, M. Ferreiro, L. Carlsson, and C. Antzelevitch Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation Heart Rhythm 5 2008 1735 1742
42. A. Burashnikov, J.M. Di Diego, A.C. Zygmunt, L. Belardinelli, and C. Antzelevitch Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine Circulation 116 2007 1449 1457 (Pubitemid 47480635)
43. A. Burashnikov, J.M. Di Diego, A.C. Zygmunt, L. Belardinelli, and C. Antzelevitch Atrial-selective sodium channel block as a strategy for suppression of atrial fibrillation Ann N Y Acad Sci 1123 2008 105 112 (Pubitemid 351431308)
44. Kur block Am J Physiol 286 2004 H2393 H2400
45. A. Burashnikov, S. Sicouri, J.M. Di Diego, L. Belardinelli, and C. Antzelevitch Synergistic effect of the combination of dronedarone and ranolazine to suppress atrial fibrillation J Am Coll Cardiol 56 2010 1216 1224
46. A. Burashnikov, A.C. Zygmunt, J.M. Di Diego, G. Linhardt, L. Carlsson, and C. Antzelevitch AZD1305 exerts atrial-predominant electrophysiological actions and is effective in suppressing atrial fibrillation and preventing its re-induction in the dog J Cardiovasc Pharmacol 56 2010 80 90
47. B. Burstein, E. Libby, A. Calderone, and S. Nattel Differential behaviors of atrial versus ventricular fibroblasts: a potential role for platelet-derived growth factor in atrial-ventricular remodeling differences Circulation 117 2008 1630 1641 (Pubitemid 351482606)
48. A.J. Camm, P. Kirchhof, G.Y. Lip, U. Schotten, I. Savelieva, and S. Ernst Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC) Eur Heart J 12 2010 1360 1420
49. L. Carlsson, D. Chartier, and S. Nattel Characterization of the in vivo and in vitro electrophysiological effects of the novel antiarrhythmic agent AZD7009 in atrial and ventricular tissue of the dog J Cardiovasc Pharmacol 47 2006 123 132 (Pubitemid 44378235)
50. E. Carmeliet Electrophysiologic and voltage clamp analysis of the effects of sotalol on isolated cardiac muscle and Purkinje fibers J Pharmacol Exp Ther 232 1985 817 825 (Pubitemid 15135875)
51. T.J. Cha, J.R. Ehrlich, D. Chartier, X.Y. Qi, L. Xiao, and S. Nattel Kir3-based inward rectifier potassium current: potential role in atrial tachycardia remodeling effects on atrial repolarization and arrhythmias Circulation 113 2006 1730 1737 (Pubitemid 43958465)
52. C.C. Chou, M. Nihei, S. Zhou, A. Tan, A. Kawase, and E.S. Macias Intracellular calcium dynamics and anisotropic reentry in isolated canine pulmonary veins and left atrium Circulation 111 2005 2889 2897 (Pubitemid 40814181)
53. T. Christ, E. Wettwer, N. Voigt, O. Hala, S. Radicke, and K. Matschke Pathology-specific effects of the IKur/Ito/IK, ACh blocker AVE0118 on ion channels in human chronic atrial fibrillation Br J Pharmacol 154 2008 1619 1630
54. + channels in rabbit atrial and ventricular cardiomyocytes Eur J Pharmacol 373 1999 223 232 (Pubitemid 29306732)
55. S.K. Chua, P.C. Chang, M. Maruyama, I. Turker, T. Shinohara, and M.J. Shen Small-conductance calcium-activated potassium channel and recurrent ventricular fibrillation in failing rabbit ventricles Circ Res 108 2011 971 979
56. + channel blockers. Insights from mathematical models and experimental correlates Am J Physiol Heart Circ Physiol 295 2008 H1489 H1504
57. S.D. Corley, A.E. Epstein, J.P. DiMarco, M.J. Domanski, N. Geller, and H.L. Greene Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study Circulation 109 2004 1509 1513 (Pubitemid 38420179)
58. F.G. Cosio, E. Aliot, G.L. Botto, H. Heidbuchel, C.J. Geller, and P. Kirchhof Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the first detected episode Europace 10 2008 21 27 (Pubitemid 351767271)
59. D. Cotiga, A. Arshad, E. Aziz, S. Joshi, J.N. Koneru, and J.S. Steinberg Acute conversion of persistent atrial fibrillation during dofetilide initiation PACE 30 2007 1527 1530 (Pubitemid 350198266)
60. H.J. Crijns, G.I. Van, H. Walfridsson, P. Kulakowski, A. Ronaszeki, and V. Dedek Safe and effective conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009 Heart Rhythm 3 2006 1321 1331 (Pubitemid 44636926)
61. P.C. Deedwania, B.N. Singh, K. Ellenbogen, S. Fisher, R. Fletcher, and S.N. Singh Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators Circulation 98 1998 2574 2579 (Pubitemid 29001197)
62. S. Dhein, A. Hagen, J. Jozwiak, A. Dietze, J. Garbade, and M. Barten Improving cardiac gap junction communication as a new antiarrhythmic mechanism: the action of antiarrhythmic peptides Naunyn Schmiedebergs Arch Pharmacol 381 2010 221 234
63. + channels terminates and protects against atrial fibrillation Circ Arrhythm Electrophysiol 3 2010 380 390
64. M. Disertori, R. Latini, S. Barlera, M.G. Franzosi, L. Staszewsky, and A.P. Maggioni Valsartan for prevention of recurrent atrial fibrillation N Engl J Med 360 2009 1606 1617
65. D. Dobrev, A. Friedrich, N. Voigt, N. Jost, E. Wettwer, and T. Christ The G protein-gated potassium current IK, ACh is constitutively active in patients with chronic atrial fibrillation Circulation 112 2005 3697 3706 (Pubitemid 43739509)
66. D. Dobrev, and S. Nattel Calcium handling abnormalities in atrial fibrillation as a target for innovative therapeutics J Cardiovasc Pharmacol 52 2008 293 299
67. P. Dorian, A. Pinter, I. Mangat, V. Korley, S.S. Cvitkovic, and G.N. Beatch The effect of vernakalant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humans J Cardiovasc Pharmacol 50 2007 35 40 (Pubitemid 47220444)
68. R.N. Doughty, A. Rodgers, N. Sharpe, and S. MacMahon Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials Eur Heart J 18 1997 560 565 (Pubitemid 27182346)
69. A. Ducharme, K. Swedberg, M.A. Pfeffer, A. Cohen-Solal, C.B. Granger, and A.P. Maggioni Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of reduction in mortality and morbidity (CHARM) program Am Heart J 152 2006 86 92
70. S.C. Dudley Jr., N.E. Hoch, L.A. McCann, C. Honeycutt, L. Diamandopoulos, and T. Fukai Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: role of the NADPH and xanthine oxidases Circulation 112 2005 1266 1273 (Pubitemid 41268651)
71. M. Duytschaever, Y. Blaauw, and M. Allessie Consequences of atrial electrical remodeling for the anti-arrhythmic action of class IC and class III drugs Cardiovasc Res 67 2005 69 76 (Pubitemid 40803460)
72. D.S. Echt, L.E. Berte, W.T. Clusin, R.G. Samuelson, D.C. Harrison, and J.W. Mason Prolongation of the human monophasic action potential by sotalol Am J Cardiol 50 1982 1082 1086 (Pubitemid 13232034)
73. J.R. Ehrlich, P. Biliczki, S.H. Hohnloser, and S. Nattel Atrial-selective approaches for the treatment of atrial fibrillation J Am Coll Cardiol 51 2008 787 792 (Pubitemid 351253743)
74. J.R. Ehrlich, T.J. Cha, L. Zhang, D. Chartier, L. Villeneuve, and T.E. Hebert Characterization of a hyperpolarization-activated time-dependent potassium current in canine cardiomyocytes from pulmonary vein myocardial sleeves and left atrium J Physiol 557 2004 583 597 (Pubitemid 38807396)
75. J.R. Ehrlich, and S. Nattel Atrial-selective pharmacological therapy for atrial fibrillation: hype or hope? Curr Opin Cardiol 24 2009 50 55
76. P.T. Ellinor, K.L. Lunetta, N.L. Glazer, A. Pfeufer, A. Alonso, and M.K. Chung Common variants in KCNN3 are associated with lone atrial fibrillation Nat Genet 42 2010 240 244
77. D. Fedida Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent Expert Opin Investig Drugs 16 2007 519 532 (Pubitemid 46554469)
78. + current in canine atrial myocytes Circ Res 93 2003 744 751 (Pubitemid 37288669)
79. G. Fenelon, R.K. Shepard, and B.S. Stambler Focal origin of atrial tachycardia in dogs with rapid ventricular pacing-induced heart failure J Cardiovasc Electrophysiol 14 2003 1093 1102 (Pubitemid 37412088)
80. J. Feng, D. Xu, Z. Wang, and S. Nattel Ultrarapid delayed rectifier current inactivation in human atrial myocytes: properties and consequences Am J Physiol 275 1998 H1717 H1725
81. ATP channels require SUR1 Circ Res 103 2008 1458 1465
82. Kur): rationale, pharmacology and evidence for potential therapeutic value J Cardiovasc Pharmacol 52 2008 105 120
83. A. Frustaci, C. Chimenti, F. Bellocci, E. Morgante, M.A. Russo, and A. Maseri Histological substrate of atrial biopsies in patients with lone atrial fibrillation Circulation 96 1997 1180 1184 (Pubitemid 27344221)
84. V. Fuster, L.E. Ryden, D.S. Cannom, H.J. Crijns, A.B. Curtis, and K.A. Ellenbogen ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) J Am Coll Cardiol 48 2006 854 906 (Pubitemid 44175743)
85. V. Fuster, L.E. Ryden, D.S. Cannom, H.J. Crijns, A.B. Curtis, and K.A. Ellenbogen 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society J Am Coll Cardiol 57 2011 e101 e198
86. N. Gaborit, B.S. Le, V. Szuts, A. Varro, D. Escande, and S. Nattel Regional and tissue specific transcript signatures of ion channel genes in the non-diseased human heart J Physiol 582 2007 675 693 (Pubitemid 47040552)
87. J.C. Geller, K. Egstrup, P. Kulakowski, M. Rosenqvist, M.A. Jansson, and A. Berggren Rapid conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009 J Clin Pharmacol 49 2009 312 322
88. A.S. Go, E.M. Hylek, K.A. Phillips, Y. Chang, L.E. Henault, and J.V. Selby Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study JAMA 285 2001 2370 2375 (Pubitemid 32424106)
89. A. Goette, A. Bukowska, and U. Lendeckel Non-ion channel blockers as anti-arrhythmic drugs (reversal of structural remodeling) Curr Opin Pharmacol 7 2007 219 224 (Pubitemid 46404738)
90. R.N. Goldstein, C. Khrestian, L. Carlsson, and A.L. Waldo Azd7009: a new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model J Cardiovasc Electrophysiol 15 2004 1444 1450 (Pubitemid 40013678)
91. J.M. Guerra, T.H. Everett, K.W. Lee, E. Wilson, and J.E. Olgin Effects of the gap junction modifier rotigaptide (ZP123) on atrial conduction and vulnerability to atrial fibrillation Circulation 114 2006 110 118 (Pubitemid 44420742)
92. M. Guglin, R. Chen, and A.B. Curtis Sinus rhythm is associated with fewer heart failure symptoms: insights from the AFFIRM trial Heart Rhythm 7 2010 596 601
93. ATP channel J Cardiovasc Electrophysiol 20 2009 93 98
94. N. Hanna, S. Cardin, T.K. Leung, and S. Nattel Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure Cardiovasc Res 63 2004 236 244 (Pubitemid 38900838)
95. N. Hashimoto, T. Yamashita, and N. Tsuruzoe Tertiapin, a selective IK, ACh blocker, terminates atrial fibrillation with selective atrial effective refractory period prolongation Pharmacol Res 54 2006 136 141 (Pubitemid 44038385)
96. J.S. Healey, A. Baranchuk, E. Crystal, C.A. Morillo, M. Garfinkle, and S. Yusuf Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis J Am Coll Cardiol 45 2005 1832 1839 (Pubitemid 40789940)
97. H. Heidbuchel, G. Callewaert, J. Vereecke, and E. Carmeliet Membrane-bound nucleoside diphosphate kinase activity in atrial cells of frog, guinea pig, and human Circ Res 71 1992 808 820
98. M. Hirose, and K.R. Laurita Calcium-mediated triggered activity is an underlying cellular mechanism of ectopy originating from the pulmonary vein in dogs Am J Physiol Heart Circ Physiol 292 2007 H1861 H1867
99. S.H. Hohnloser, K.H. Kuck, and J. Lilienthal Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial Lancet 356 2000 1789 1794
100. L. Hove-Madsen, A. Llach, A. Bayes-Genis, S. Roura, F.E. Rodriguez, and A. Aris Atrial fibrillation is associated with increased spontaneous calcium release from the sarcoplasmic reticulum in human atrial myocytes Circulation 110 2004 1358 1363 (Pubitemid 39238013)
101. 2+ release channels (RyR2) determines efficacy of Class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia Circ Arrhythm Electrophysiol 4 2011 128 135
102. C.A.S.T. Investigators Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction N Engl J Med 321 1989 406 412
103. C.R. Kerr, K.H. Humphries, M. Talajic, G.J. Klein, S.J. Connolly, and M. Green Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry of Atrial Fibrillation Am Heart J 149 2005 489 496 (Pubitemid 40585413)
104. P. Kirchhof, J. Bax, C. Blomstrom-Lundquist, H. Calkins, A.J. Camm, and R. Cappato Early and comprehensive management of atrial fibrillation: proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation' Europace 11 2009 860 885
105. P. Kirchhof, L. Eckardt, M.R. Franz, G. Monnig, P. Loh, and H. Wedekind Prolonged atrial action potential durations and polymorphic atrial tachyarrhythmias in patients with long QT syndrome J Cardiovasc Electrophysiol 14 2003 1027 1033 (Pubitemid 37412078)
106. J. Kneller, J. Kalifa, R. Zou, A.V. Zaitsev, M. Warren, and O. Berenfeld Mechanisms of atrial fibrillation termination by pure sodium channel blockade in an ionically-realistic mathematical model Circ Res 96 2005 e35 e47
107. K. Knobloch, J. Brendel, B. Rosenstein, M. Bleich, A.E. Busch, and K.J. Wirth Atrial-selective antiarrhythmic actions of novel Ikur vs. Ikr, Iks, and IKAch class Ic drugs and beta blockers in pigs Med Sci Monit 10 2004 BR221 BR228
108. L. Kober, C. Torp-Pedersen, J.J. McMurray, O. Gotzsche, S. Levy, and H. Crijns Increased mortality after dronedarone therapy for severe heart failure N Engl J Med 358 2008 2678 2687 (Pubitemid 351860860)
109. S. Kostin, G. Klein, Z. Szalay, S. Hein, E.P. Bauer, and J. Schaper Structural correlate of atrial fibrillation in human patients Cardiovasc Res 54 2002 361 379 (Pubitemid 34327915)
110. P.R. Kowey, J.A. Reiffel, K.A. Ellenbogen, G.V. Naccarelli, and C.M. Pratt Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial JAMA 304 2010 2363 2372
111. K. Kumagai, H. Nakashima, N. Gondo, and K. Saku Antiarrhythmic effects of JTV-519, a novel cardioprotective drug, on atrial fibrillation/flutter in a canine sterile pericarditis model J Cardiovasc Electrophysiol 14 2003 880 884 (Pubitemid 36994108)
112. K. Kumar, B.D. Nearing, M. Carvas, B.C. Nascimento, M. Acar, and L. Belardinelli Ranolazine exerts potent effects on atrial electrical properties and abbreviates atrial fibrillation duration in the intact porcine heart J Cardiovasc Electrophysiol 20 2009 796 802
113. G. Laurent, H. Leong-Poi, I. Mangat, G.W. Moe, X. Hu, and P.P. So Effects of chronic gap junction conduction-enhancing antiarrhythmic peptide GAP-134 administration on experimental atrial fibrillation in dogs Circ Arrhythm Electrophysiol 2 2009 171 178
114. S. Le Bouter, A. El Harchi, C. Marionneau, C. Bellocq, A. Chambellan, and T. van Veen Long-term amiodarone administration remodels expression of ion channel transcripts in the mouse heart Circulation 110 2004 3028 3035 (Pubitemid 39491994)
115. J.Y. Le Heuzey, G.M. De Ferrari, D. Radzik, M. Santini, J. Zhu, and J.M. Davy A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study J Cardiovasc Electrophysiol 21 2010 597 605
116. D. Li, P. Melnyk, J. Feng, Z. Wang, K. Petrecca, and A. Shrier Effects of experimental heart failure on atrial cellular and ionic electrophysiology Circulation 101 2000 2631 2638 (Pubitemid 30350643)
117. + current in human atrial myocytes Cardiovasc Res 81 2009 286 293
118. + channel (SK2 channel) results in action potential prolongation in atrial myocytes and atrial fibrillation J Physiol 587 2009 1087 1100
119. G.R. Li, H.B. Wang, G.W. Qin, M.W. Jin, Q. Tang, and H.Y. Sun Acacetin, a natural flavone, selectively inhibits human atrial repolarization potassium currents and prevents atrial fibrillation in dogs Circulation 117 2008 2449 2457 (Pubitemid 351670451)
120. Kur-blockade in vivo strial electrical remodeling and antiarrhythmic drugs J Cardiovasc Electrophysiol 18 2007 1313 1320 (Pubitemid 350115783)
121. S.A. Lubitz, B.A. Yi, and P.T. Ellinor Genetics of atrial fibrillation Cardiol Clin 27 2009 25 33
122. A.P. Maggioni, G. Fabbri, D. Lucci, R. Marchioli, M.G. Franzosi, and R. Latini Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial Eur Heart J 19 2009 2327 2336
123. Na using ranolazine J Cardiovasc Pharmacol 54 2009 279 286
124. T. Matsuda, K. Takeda, M. Ito, R. Yamagishi, M. Tamura, and H. Nakamura Atria selective prolongation by NIP-142, an antiarrhythmic agent, of refractory period and action potential duration in guinea pig myocardium J Pharmacol Sci 98 2005 33 40 (Pubitemid 40806125)
125. A. Medeiros-Domingo, B.H. Tan, L. Crotti, D.J. Tester, L. Eckhardt, and A. Cuoretti Gain-of-function mutation S422L in the KCNJ8-encoded cardiac K(ATP) channel Kir6.1 as a pathogenic substrate for J-wave syndromes Heart Rhythm 7 2010 1466 1471
126. Y. Miyasaka, M.E. Barnes, B.J. Gersh, S.S. Cha, K.R. Bailey, and W.P. Abhayaratna Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence Circulation 114 2006 119 125 (Pubitemid 44420743)
127. D.K. Murdock, M. Kersten, J. Kaliebe, and G. Larrian The use of oral ranolazine to convert new or paroxysmal atrial fibrillation: a reveiw of experience with implications for possible "pill in the pocket" approach to atrial fibrillation Indian Pacing Electrophysiol J 9 2009 260 267
128. D.K. Murdock, N. Overton, M. Kersten, J. Kaliebe, and F. Devecchi The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation Indian Pacing Electrophysiol J 8 2008 175 181
129. D.K. Murdock, J.A. Reiffel, J.W. Kaliebe, and G. Larrian The conversion of paroxysmal of initial onset of atrial fibrillation with oral ranolazine: implications for "pill in the pocket" approach in structural heart disease J Am Coll Cardiol 55 A6 2010 E58 [Abstract]
130. A. Nabar, L.M. Rodriguez, C. Timmermans, M.R. van, and H.J. Wellens Class IC antiarrhythmic drug induced atrial flutter: electrocardiographic and electrophysiological findings and their importance for long term outcome after right atrial isthmus ablation Heart 85 2001 424 429 (Pubitemid 32973531)
131. 1 transgene in the heart Circ Res 86 2000 571 579 (Pubitemid 30165049)
132. S. Nattel New ideas about atrial fibrillation 50 years on Nature 415 2002 219 226 (Pubitemid 34059528)
133. S. Nattel, and L. Carlsson Innovative approaches to anti-arrhythmic drug therapy Nat Drug Discov 5 2006 1034 1049 (Pubitemid 44835130)
134. S. Nattel, B. Burstein, and D. Dobrev Atrial remodeling and atrial fibrillation: mechanisms and implications Circ Arrhythm Electrophysiol 1 2008 62 73
135. S. Nattel, C. Matthews, E. De Blasio, W. Han, D. Li, and L. Yue Dose-dependence of 4-aminopyridine plasma concentrations and electrophysiological effects in dogs: potential relevance to ionic mechanisms in vivo Circulation 101 2000 1179 1184 (Pubitemid 30146621)
136. T.M. Olson, A.E. Alekseev, X.K. Liu, S.J. Park, L.V. Zingman, and M. Bienengraeber Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation Hum Mol Genet 15 2006 2185 2191 (Pubitemid 43985509)
137. ATP channel mutation confers risk for vein of Marshall adrenergic atrial fibrillation Nat Clin Pract Cardiovasc Med 4 2007 110 116 (Pubitemid 46165273)
138. G. Opolski, A. Torbicki, D.A. Kosior, M. Szulc, B. Wozakowska-Kaplon, and P. Kolodziej Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study Chest 126 2004 476 486 (Pubitemid 39093433)
139. H. Oral, J.J. Souza, G.F. Michaud, B.P. Knight, R. Goyal, and S.A. Strickberger Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment N Engl J Med 340 1999 1849 1854 (Pubitemid 29272664)
140. S.V. Pandit, S. Zlochiver, D. Filgueiras-Rama, S. Mironov, M. Yamazaki, and S.R. Ennis Targeting atrio-ventricular differences in ion channel properties for terminating acute atrial fibrillation in pigs Cardiovasc Res 89 2011 843 851
141. C. Pappone, V. Santinelli, F. Manguso, G. Vicedomini, F. Gugliotta, and G. Augello Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation Circulation 109 2004 327 334 (Pubitemid 38133899)
142. E. Patterson, B.J. Scherlag, J. Zhou, W.M. Jackman, R. Lazzara, and D. Coscia Antifibrillatory actions of cisatracurium: an atrial specific m receptor antagonist J Cardiovasc Electrophysiol 19 2008 861 868 (Pubitemid 352032782)
143. O.D. Pedersen, H. Bagger, N. Keller, B. Marchant, L. Kober, and C. Torp-Pedersen Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy Circulation 104 2001 292 296 (Pubitemid 32666950)
144. J.P. Piccini, V. Hasselblad, E.D. Peterson, J.B. Washam, R.M. Califf, and D.F. Kong Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation J Am Coll Cardiol 54 2009 1089 1095
145. C.M. Pratt, A.J. Camm, W. Cooper, P.L. Friedman, D.J. Macneil, and K.M. Moulton Mortality in the survival with ORal d-sotalol (SWORD) trial: why did patients die? Am J Cardiol 81 1998 869 876 (Pubitemid 28204641)
146. U. Ravens Potassium channels in atrial fibrillation: targets for atrial and pathology-specific therapy? Heart Rhythm 5 2008 758 759
147. U. Ravens Antiarrhythmic therapy in atrial fibrillation Pharmacol Ther 128 2010 129 145
148. U. Ravens, and E. Wettwer Ultra-rapid delayed rectifier channels: molecular basis and therapeutic implications Cardiovasc Res 89 2011 843 851
149. Kur blockers 3-[(dimethylamino)methyl]-6-methoxy-2-methyl-4- phenylisoquinolin-1(2H)-one and 2-phenyl-1,1-dipyridin-3-yl-2-pyrrolidin-1-yl- ethanol in dogs with underlying heart failure J Pharmacol Exp Ther 324 2008 322 330 (Pubitemid 350294153)
150. C.P. Regan, G.L. Stump, A.A. Wallace, K.D. Anderson, C.J. McIntyre, and N.J. Liverton In vivo cardiac electrophysiologic and antiarrhythmic effects of an isoquinoline IKur blocker, ISQ-1, in rat, dog, and nonhuman primate J Cardiovasc Pharmacol 49 2007 236 245 (Pubitemid 46626016)
151. J.A. Reiffel Atrial fibrillation: what have recent trials taught us regarding pharmacologic management of rate and rhythm control? Pacing Clin Electrophysiol 34 2011 247 259
152. M. Rienstra, G.I. Van, V.E. Hagens, N.J. Veeger, D.J. Van Veldhuisen, and H.J. Crijns Mending the rhythm does not improve prognosis in patients with persistent atrial fibrillation: a subanalysis of the RACE study Eur Heart J 27 2006 357 364 (Pubitemid 43100033)
153. K.C. Roberts-Thomson, I. Stevenson, P.M. Kistler, H.M. Haqqani, S.J. Spence, and J.C. Goldblatt The role of chronic atrial stretch and atrial fibrillation on posterior left atrial wall conduction Heart Rhythm 6 2009 1109 1117
154. A. Ronaszeki, M. Alings, K. Egstrup, Z. Gaciong, M. Hranai, and C. Kiraly Pharmacological cardioversion of atrial fibrillation-a double-blind, randomized, placebo-controlled, multicentre, dose-escalation study of AZD1305 given intravenously Europace 13 2011 1148 1156
155. J.F. Roux, E. Zado, D.J. Callans, F. Garcia, D. Lin, and F.E. Marchlinski Antiarrhythmics after ablation of atrial fibrillation (5A study) Circulation 120 2009 1036 1040
156. D. Roy, M. Talajic, P. Dorian, S. Connolly, M.J. Eisenberg, and M. Green Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators N Engl J Med 342 2000 913 920 (Pubitemid 30177051)
157. D. Roy, M. Talajic, M. Dubuc, B. Thibault, P. Guerra, and L. Macle Atrial fibrillation and congestive heart failure Curr Opin Cardiol 24 2009 29 34
158. D. Roy, M. Talajic, S. Nattel, D.G. Wyse, P. Dorian, and K.L. Lee Rhythm control versus rate control for atrial fibrillation and heart failure N Engl J Med 358 2008 2667 2677 (Pubitemid 351860859)
159. O. Salehian, J. Healey, B. Stambler, K. Alnemer, K. Almerri, and J. Grover Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study Am Heart J 154 2007 448 453 (Pubitemid 47271928)
160. I. Savelieva, and J. Camm Statins and polyunsaturated fatty acids for treatment of atrial fibrillation Nat Clin Pract Cardiovasc Med 5 2008 30 41
161. I. Savelieva, N. Kakouros, A. Kourliouros, and A.J. Camm Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention Europace 13 2011 308 328
162. I. Savelieva, N. Kakouros, A. Kourliouros, and A.J. Camm Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention Europace 13 2011 610 625
163. 2+-exchange Cardiovasc Res 73 2007 37 47 (Pubitemid 44937207)
164. G. Schram, L. Zhang, K. Derakhchan, J.R. Ehrlich, L. Belardinelli, and S. Nattel Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects Br J Pharmacol 142 2004 1300 1308 (Pubitemid 39185852)
165. + channel Kv1.5 Circ Res 104 2009 1390 1398
166. G.G. Schwartz, B.R. Chaitman, J.J. Goldberger, and M. Messig High-dose atorvastatin and risk of atrial fibrillation in patients with prior stroke or transient ischemic attack: analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial Am Heart J 161 2011 993 999
167. B.M. Scirica, D.A. Morrow, H. Hod, S.A. Murphy, L. Belardinelli, and C.M. Hedgepeth Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency with Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial Circulation 116 2007 1647 1652 (Pubitemid 47537839)
168. A. Seki, N. Hagiwara, and H. Kasanuki Effects of NIP-141 on K currents in human atrial myocytes J Cardiovasc Pharmacol 39 2002 29 38 (Pubitemid 34028550)
169. M. Shimano, Y. Tsuji, Y. Inden, K. Kitamura, T. Uchikawa, and S. Harata Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure Heart Rhythm 5 2008 451 459
170. W. Shimizu, and C. Antzelevitch Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome J Am Coll Cardiol 35 2000 778 786 (Pubitemid 30167037)
171. A. Shiroshita-Takeshita, M. Sakabe, K. Haugan, J.K. Hennan, and S. Nattel Model-dependent effects of the gap junction conduction-enhancing antiarrhythmic peptide rotigaptide (ZP123) on experimental atrial fibrillation in dogs Circulation 115 2007 310 318 (Pubitemid 46151658)
172. S. Sicouri, A. Burashnikov, L. Belardinelli, and C. Antzelevitch Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria Circ Arrhythm Electrophysiol 3 2010 88 95
173. S. Sicouri, B. Gianetti, A.C. Zygmunt, J.M. Cordeiro, and C. Antzelevitch Antiarrhythmic effects of simvastatin in canine pulmonary vein sleeve preparations J Am Coll Cardiol 57 2011 986 993
174. B.N. Singh Amiodarone: a multifaceted antiarrhythmic drug Curr Cardiol Rep 8 2006 349 355 (Pubitemid 44445922)
175. D. Singh, E. Cingolani, G.A. Diamond, and S. Kaul Dronedarone for atrial fibrillation: have we expanded the antiarrhythmic armamentarium? J Am Coll Cardiol 55 2010 1569 1576
176. S. Sood, M.G. Chelu, R.J. van Oort, D. Skapura, M. Santonastasi, and D. Dobrev Intracellular calcium leak due to FKBP12.6 deficiency in mice facilitates the inducibility of atrial fibrillation Heart Rhythm 5 2008 1047 1054
177. + currents in atrial fibrillation: effects of ranolazine on arrhythmias and contractility in human atrial myocardium J Am Coll Cardiol 55 2010 2330 2342
178. W. Spinelli, R.W. Parsons, and T.J. Colatsky Effects of WAY-123,398, a new class III antiarrhythmic agent, on cardiac refractoriness and ventricular fibrillation threshold in anesthetized dogs: a comparison with UK-68798, E-4031, and dl-sotalol J Cardiovasc Pharmacol 20 1992 913 922 (Pubitemid 23001457)
179. M.K. Stiles, B. John, C.X. Wong, P. Kuklik, A.G. Brooks, and D.H. Lau Paroxysmal lone atrial fibrillation is associated with an abnormal atrial substrate: characterizing the "second factor" J Am Coll Cardiol 53 2009 1182 1191
180. G.L. Stump, A.A. Wallace, C.P. Regan, and J.J. Lynch Jr. In vivo antiarrhythmic and cardiac electrophysiologic effects of a novel diphenylphosphine oxide IKur blocker (2-isopropyl-5-methylcyclohexyl) diphenylphosphine oxide J Pharmacol Exp Ther 315 2005 1362 1367 (Pubitemid 41635426)
181. T. Szel, I. Koncz, N. Jost, I. Baczko, Z. Husti, and L. Virag Class I/B antiarrhythmic property of ranolazine, a novel antianginal agent, in dog and human cardiac preparations Eur J Pharmacol 662 2011 31 39
182. M. Talajic, P. Khairy, S. Levesque, S.J. Connolly, P. Dorian, and M. Dubuc Maintenance of sinus rhythm and survival in patients with heart failure and atrial fibrillation J Am Coll Cardiol 55 2010 1796 1802
183. C.T. Tsai, L.P. Lai, K.T. Kuo, J.J. Hwang, C.S. Hsieh, and K.L. Hsu Angiotensin II activates signal transducer and activators of transcription 3 via Rac1 in atrial myocytes and fibroblasts: implication for the therapeutic effect of statin in atrial structural remodeling Circulation 117 2008 344 355
184. H.F. Tse, and C.P. Lau Electrophysiologic actions of dl-sotalol in patients with persistent atrial fibrillation J Am Coll Cardiol 40 2002 2150 2155
185. + channels SK1, SK2, and SK3 in mouse atrial and ventricular myocytes Am J Physiol Heart Circ Physiol 289 2005 H2714 H2723
186. I. Van Gelder, V.E. Hagens, H.A. Bosker, J.H. Kingma, O. Kamp, and T. Kingma A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation N Engl J Med 347 2002 1834 1840 (Pubitemid 35417774)
187. D.R. Van Wagoner Oxidative stress and inflammation in atrial fibrillation: role in pathogenesis and potential as a therapeutic target J Cardiovasc Pharmacol 52 2008 306 313
188. + current densities and Kv1.5 expression are reduced in chronic human atrial fibrillation Circ Res 80 1997 772 781 (Pubitemid 27230051)
189. S. Verheule, T. Sato, T. Everett, S.K. Engle, D. Otten, and L.M. Rubart-von der Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1 Circ Res 94 2004 1458 1465 (Pubitemid 38780318)
190. S. Verheule, E. Wilson, T. Everett, S. Shanbhag, C. Golden, and J. Olgin Alterations in atrial electrophysiology and tissue structure in a canine model of chronic atrial dilatation due to mitral regurgitation Circulation 107 2003 2615 2622 (Pubitemid 36628945)
191. J.A. Vest, X.H. Wehrens, S.R. Reiken, S.E. Lehnart, D. Dobrev, and P. Chandra Defective cardiac ryanodine receptor regulation during atrial fibrillation Circulation 111 2005 2025 2032 (Pubitemid 40577896)
192. N. Voigt, A. Friedrich, M. Bock, E. Wettwer, T. Christ, and M. Knaut Differential phosphorylation-dependent regulation of constitutively active and muscarinic receptor-activated IK, ACh channels in patients with chronic atrial fibrillation Cardiovasc Res 74 2007 426 437 (Pubitemid 46693702)
193. A.L. Waldo, A.J. Camm, H. DeRuyter, P.L. Friedman, D.J. Macneil, and J.F. Pauls Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD investigators. Survival with oral d-Sotalol Lancet 348 1996 7 12 (Pubitemid 26237238)
194. J. Wang, J. Feng, and S. Nattel Class III antiarrhythmic drug action in experimental atrial fibrillation. Differences in reverse use dependence and effectiveness between d-sotalol and the new antiarrhythmic drug ambasilid Circulation 90 1994 2032 2040 (Pubitemid 24320956)
195. + current similar to Kv1.5 cloned channel currents Circ Res 73 1993 1061 1076 (Pubitemid 23340202)
196. H. Watanabe, I. Watanabe, T. Nakai, N. Oshikawa, S. Kunimoto, and R. Masaki Frequency-dependent electrophysiological effects of flecainide, nifekalant and d, l-sotalol on the human atrium Jpn Circ J 65 2001 1 6
197. Kur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation Circulation 110 2004 2299 2306 (Pubitemid 39407330)
198. A.C. Wiesfeld, C.D. De Langen, H.J. Crijns, K.J. Bel, H.L. Hillege, and H. Wesseling Rate-dependent effects of the class III antiarrhythmic drug almokalant on refractoriness in the pig J Cardiovasc Pharmacol 27 1996 594 600 (Pubitemid 26107149)
199. M.C. Wijffels, C.J. Kirchhof, R. Dorland, and M.A. Allessie Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats Circulation 92 1995 1954 1968
200. K.J. Wirth, J. Brendel, K. Steinmeyer, D.K. Linz, H. Rutten, and H. Gogelein In vitro and in vivo effects of the atrial selective antiarrhythmic compound AVE1231 J Cardiovasc Pharmacol 49 2007 197 206 (Pubitemid 46626011)
201. K.J. Wirth, J. Brendel, K. Steinmeyer, D.K. Linz, H. Rutten, and H. Gogelein In vitro and in vivo effects of the atrial selective antiarrhythmic compound AVE1231 J Cardiovasc Pharmacol 49 2007 197 206 (Pubitemid 46626011)
202. A.J. Workman, K.A. Kane, and A.C. Rankin Cellular bases for human atrial fibrillation Heart Rhythm 5 2008 S1 S6
203. L. Wu, S. Rajamani, J.C. Shryock, H. Li, J. Ruskin, and C. Antzelevitch Augmentation of late sodium current unmasks the proarrhythmic effects of amiodarone Cardiovasc Res 77 2008 481 488 (Pubitemid 351197663)
204. D.G. Wyse Cardioversion of atrial fibrillation for maintenance of sinus rhythm: a road to nowhere Circulation 120 2009 1444 1452
205. D.G. Wyse, A.L. Waldo, J.P. DiMarco, M.J. Domanski, Y. Rosenberg, and E.B. Schron A comparison of rate control and rhythm control in patients with atrial fibrillation N Engl J Med 347 2002 1825 1833 (Pubitemid 35417773)
206. H.D. Xiao, S. Fuchs, D.J. Campbell, W. Lewis, S.C. Dudley Jr., and V.S. Kasi Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death Am J Pathol 165 2004 1019 1032 (Pubitemid 39129307)
207. Y. Yang, J. Li, X. Lin, Y. Yang, K. Hong, and L. Wang Novel KCNA5 loss-of-function mutations responsible for atrial fibrillation J Hum Genet 54 2009 277 283
208. T. Yang, P. Yang, D.M. Roden, and D. Darbar Novel KCNA5 mutation implicates tyrosine kinase signaling in human atrial fibrillation Heart Rhythm 7 2010 1246 1252
209. S. Yusuf, J.S. Healey, J. Pogue, S. Chrolavicius, M. Flather, and R.G. Hart Irbesartan in patients with atrial fibrillation N Engl J Med 364 2011 928 938
210. S. Zhou, C.M. Chang, T.J. Wu, Y. Miyauchi, Y. Okuyama, and A.M. Park Nonreentrant focal activations in pulmonary veins in canine model of sustained atrial fibrillation Am J Physiol Heart Circ Physiol 283 2002 H1244 H1252
211. P. Zimetbaum Amiodarone for atrial fibrillation N Engl J Med 356 2007 935 941